Patient-Specific Cutting Guides for Joint Arthroplasty

Introduction

Three-dimensional (3-D) printing technology is being used as part of some joint replacement surgeries. Standard cutting guides — which show where the bone is to be cut — are available and widely used. But 3-D printing allows for custom cutting guides to be created for an individual patient. For a custom cutting guide, an MRI or CT scan is taken before the surgery. The image is then sent out to a company that creates a mold. During surgery, that mold is then fitted over the end of the bone to guide where the bone should be cut. Published studies show that custom cutting guides don’t result in better alignment than standard cutting guides. Some studies show the custom materials create worse alignment. More and larger studies are needed to determine how well these custom cutting guides work. For this reason, custom cutting guides are considered investigational (unproven).

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.
Patient-specific instrumentation (eg, cutting guides) for joint arthroplasty, including but not limited to use in unicompartmental or total knee arthroplasty, is considered investigational.

Coding

There are no specific codes for this instrumentation. The joint arthroplasty procedure would be reported using the regular CPT codes for that surgery.

Related Information

N/A

Evidence Review

Description

Patient-specific instrumentation (PSI) has been developed as an alternative to conventional cutting guides for joint arthroplasty. Patient-specific cutting guides are constructed with the aid of preoperative 3-dimensional computed tomography (CT) or magnetic resonance imaging (MRI) scans and proprietary planning software. The goals of patient-specific instrumentation are to increase surgical efficiency and to improve implant alignment and clinical outcomes.
Background

**Total Knee Arthroplasty**

Total knee arthroplasty (TKA; also called knee replacement) is an established treatment for relief from significant, disabling pain caused by advanced arthritis. TKA is considered among the most successful medical procedures in the United States regarding the degree of improvement in functional status and quality of life. As a result of the success of TKA, the increase in the aging population, and the desire of older adults to remain physically active, the incidence of TKA is increasing rapidly. It is projected that by 2030, the demand for knee replacement will approach 3.5 million procedures annually.\(^1\)

TKA is performed by removing the damaged cartilage surface and a portion of underlying bone using a saw guided by templates and jigs. The cartilage and bone removed from the distal femur and proximal tibia are replaced with implants that recreate the surface of the joint. Patellar resurfacing may also be performed. Three-dimensional implant alignment (coronal, sagittal, axial) is considered to be critical for joint articulation and implant longevity. Less than 3° deviation from the rotational or mechanical axis, as determined by a straight line through the center of the hip, knee, and ankle on the coronal plane, is believed to minimize the risk of implant wear, loosening, instability, and pain.

**Cutting Guides**

The placement of conventional cutting guides (templates and jigs) is based on anatomic landmarks or computer navigation. Use of conventional instrumentation has been shown to result in malalignment of approximately one-third of implants in the coronal plane.\(^2\) Computer-assisted navigation can significantly reduce the proportion of malaligned implants compared with conventional instrumentation, but has a number of limitations including a lack of rotational alignment, increased surgical time, and a long learning curve. Also, no studies have demonstrated an improvement in clinical outcomes with computer-assisted navigation compared with conventional instrumentation.

Patient-specific instrumentation has been developed as an alternative to conventional cutting guides, with the goal of improving both alignment and surgical efficiency. A number of patient-specific cutting guides are currently being marketed (see the **Regulatory Status** section). Patient-specific guides are constructed with the use of preoperative 3-dimensional computed tomography or magnetic resonance imaging scans, which are taken 4 to 6 weeks before the surgery. The images are sent to the planner/manufacturer to create a 3-dimensional model of
the knee and proposed implant. After the surgeon reviews the model of the bone, makes adjustments, and approves the surgical plan, the manufacturer fabricates the disposable cutting guides.

The proposed benefits of using patient-specific and instrumentation during TKA include improved alignment, decreased operative time, increased patient throughput, fewer instrument trays, reduced risk of fat embolism and intraoperative bleeding (no intramedullary canal reaming), shorter recovery, reduced postoperative pain, reduced revision rate, and reduced costs. However, the nonsurgical costs of the procedure may be increased due to the requirement for preoperative computed tomography or magnetic resonance imaging, preoperative review of the template, and fabrication of the patient-specific instrumentation. Also, the patient-specific template relies on the same anatomic landmarks as conventional TKA and does not take soft tissue balancing into account. Thus, evaluation of this technology should also address the reliability of the cutting guides and the need for intraoperative changes such as conversion to conventional instrumentation.

**Outcome Measures**

The surrogate outcome measure of a reduction in malalignment may be informative to support improvement with the new technology. However, a reduction in the percentage of malaligned implants has not been definitively shown to result in improved clinical outcomes and is, therefore, not sufficient to demonstrate an improvement in clinical outcomes. Also, because this is a relatively new technology, no long-term studies are currently available that could provide data on revision rates. It should also be noted that the design of these devices is evolving, and results from older studies may be less relevant for contemporary designs.

**Summary of Evidence**

For individuals who are undergoing total knee arthroplasty who receive patient-specific cutting guides, the evidence includes a number of randomized controlled trials, comparative cohort studies, and systematic reviews of these studies. Relevant outcomes are symptoms, functional outcomes, and quality of life. Results from the systematic reviews are mixed, finding significant improvements in some measures of implant alignment but either no improvement or worse alignment for other measures. The available systematic reviews are limited by the small size of some of the selected studies, publication bias, and differences in both planning and manufacturing of the PSI systems. Also, the designs of the devices are evolving, and some of the
studies might have assessed now obsolete PSI systems. Available results from randomized controlled trials have not shown a benefit of PSI systems in improving clinical outcome measures with follow-up currently extending out to 2 years. The evidence is insufficient to determine the effects of the technology on health outcomes.

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this policy are listed in Table 1.

Table 1. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ongoing</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02845206</td>
<td>Randomised Controlled Trial of Patient Specific Instrumentation vs Standard Instrumentation in Total Knee Arthroplasty</td>
<td>172</td>
<td>Feb 2020</td>
</tr>
<tr>
<td>NCT03148379</td>
<td>A Multi-center, Prospective, Randomized Study Comparing Surgical and Economic Parameters of Total Knee Replacement Performed With Single-use Efficiency Instruments With Patient Specific Technique (MyKnee®) Versus Traditional Metal Instruments With Conventional Surgical Technique.</td>
<td>300</td>
<td>Apr 2020</td>
</tr>
<tr>
<td>NCT01696552</td>
<td>Patient-specific Positioning Guides (PSPG) Technique Versus Conventional Technique in Total Knee Arthroplasty - a Prospective Randomized Study</td>
<td>109</td>
<td>Jan 2024</td>
</tr>
<tr>
<td>NCT02177227a</td>
<td>Attune With TruMatch TM Personalized Solutions Instruments: A Prospective Randomized Controlled Trial Comparing Clinical and Economic Outcomes in Patients With a BMI Between 30 and 50</td>
<td>184</td>
<td>Aug 2024</td>
</tr>
<tr>
<td>NCT02096393</td>
<td>A Prospective, Randomised Control Trial Assessing Clinical and Radiological Outcomes of Patient Specific Instrumentation in Total Knee Arthroplasty</td>
<td>100</td>
<td>Dec 2024</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.
a Denotes industry-sponsored or cosponsored trial.
Practice Guidelines and Position Statements

No guidelines or position statements that mention custom cutting guides or blocks for TKA were identified.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Regulatory Status

A number of patient-specific cutting block systems and custom knee implants have been cleared for marketing by the U.S. Food and Drug Administration (FDA). An example is single-use, disposable cutting guides designed and manufactured from patient imaging data (MRI/CT). The cutting guides are used to aid the surgeon intraoperatively in making the initial distal femoral and the initial proximal tibial bone cuts during TKA surgery. The cutting guides also establish the references for component orientations. Planning systems (e.g., from Materialise NV) for the personalized instruments have also been cleared for marketing by the FDA through the 510(k) process.

In 2008, The Smith & Nephew Patient Matched Instrumentation (now called Visionaire™ Patient Matched Instrumentation) was the first patient-specific cutting guide to receive FDA clearance for marketing. Other patient-specific cutting guide systems cleared for marketing include:

- MyKnee® Patient Matched Cutting Blocks (Medacta)
- Prophecy™ Pre-operative Navigation Alignment Guides (Wright Medical Technology)
- Signature™ Planner/Signature Guides (Materialise NV and Biomet)
- TruMatch® Personalized Solutions (DePuy Orthopaedics)
- Visionaire Patient Matched Cutting Blocks (Smith & Nephew)
- Zimmer® Patient Specific Instruments and Zimmer® Patient Specific Instruments Planner (Materialise NV and Zimmer)

FDA product codes: OOG
References


History

<table>
<thead>
<tr>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>01/13/15</td>
<td>New Policy. Add to Surgery section. Policy created with literature review through July 31, 2014. Custom implants or patient-specific instrumentation for knee surgery is considered investigational.</td>
</tr>
<tr>
<td>Date</td>
<td>Comments</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>08/01/16</td>
<td>Annual Review, approved July 12, 2016. No change to policy statements.</td>
</tr>
<tr>
<td>08/01/18</td>
<td>Annual Review, approved July 25, 2018. Policy updated with literature review through February 2018; references 5 and 8-12 added. Custom implants moved to new policy on 3-dimensional printed orthopedic implants. Title changed from “Patient-Specific Cutting Guides and Custom Knee Implants” to “Patient-Specific Cutting Guides for Joint Arthroplasty”.</td>
</tr>
</tbody>
</table>

**Disclaimer:** This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2018 Premera All Rights Reserved.

**Scope:** Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.
Discrimination is Against the Law

Premera Blue Cross complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability or sex.

Premera:
- Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  - Qualified sign language interpreters
  - Written information in other formats (large print, audio, accessible electronic formats, other formats)
- Provides free language services to people whose primary language is not English, such as:
  - Qualified interpreters
  - Information written in other languages

If you need these services, contact the Civil Rights Coordinator.

If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:

Civil Rights Coordinator - Complaints and Appeals
PO Box 91102, Seattle, WA 98111
Toll free 855-332-4535, Fax 425-918-5992, TTY 800-842-5357
Email AppealsDepartmentInquiries@Premera.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:

U.S. Department of Health and Human Services
200 Independence Avenue SW, Room 509F, HHH Building
Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD)

Getting Help in Other Languages

This Notice has Important Information. This notice may have important information about your application or coverage through Premera Blue Cross. There may be key dates in this notice. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost. Call 800-722-1471 (TTY: 800-842-5357).

Arabic (Arabic): يحوي هذا الإشعار معلومات هامة. قد يحتوي هذا الإشعار على معلومات مهمة يفهمها ناطقون باللغة العربية. إذا كنت ترغب في مطالعة تلك المعلومات، قد تكون هناك توصيات متعلقة بإشعار Premera Blue Cross. يركز التوجيه في تنفيذ الإجراءات، مما يخلق بذلك المعلومات المضافة بأسماء الكلمات الأخرى. يشمل:
800-722-1471 (TTY: 800-842-5357)

中文 (Chinese): 本通知有重要的讯息。本通知可能有关於您透过 Premera Blue Cross 提交的申请或保险的重要讯息。本通知可能有重要日期。您可能需要在截止日期之前採取行動，以保留您的健康保险或者費用補貼。您有權利免費用您的母語得到本訊息和幫助。請撥電話 800-722-1471 (TTY: 800-842-5357).


Kreyòl ayisyen (Creole): Avi sila a gen Enfòmasyon Empòtan ladan. Avi sila a kapab genyen enfòmasyon enpòtan konsènan aplikasyon w lan oswa konse nan kouvèti asirans lan atriav Premera Blue Cross. Kapab genyen dat ki enpòtan nan avi sila a. Ou ka gen pou pran kék aksyon avan sèten dat limit pou ka renbe kouvèti asirans sante w la oswa pou yo ka ede w avèk dispens yo. Se dwa w pou resewwa enfòmasyon sa a ak asistans nan lang ou pale a, san ou pa gen pou yeye pou sa. Rate nan 800-722-1471 (TTY: 800-842-5357).


Ilokano (Ilocano): Dayttoy a Pakdaak ket naglaon iti Napateg nga Impormacion. Dayttoy a pakdaak babain nga adda ket naglaon iti napateg nga impormasion maipanggep iti aplikasyon woy nga coverage babaen iti Premera Blue Cross. Dayttoy ket mabalbin dagiti importante a pelsa iti dayttoy a pakdaak. Mabalbin nga adda rumbeng nga aramideng nga adda sabbay dagiti partikular a naituding nga adda alpax tapo mapagtaladianey nga coverage ti salun-atyo woy nga tulong kadagiti gastos. Adda karbenganyo a mangala iti daytoy nga impormasion ken tulong ti bukodyo a pagasasao nga awan ti bayadanyo. Tumawag ti numero nga 800-722-1471 (TTY: 800-842-5357).

This notification cannot contain information important to your application or coverage by Premera Blue Cross. It does not include any action or steps you need to take to maintain your coverage or to get help.

800-722-1471 (TTY: 800-842-5357)